ZIOPHARM Oncology (ZIOP) Upgraded by BidaskClub to Buy

Share on StockTwits

BidaskClub upgraded shares of ZIOPHARM Oncology (NASDAQ:ZIOP) from a hold rating to a buy rating in a report released on Thursday.

Several other research firms have also issued reports on ZIOP. Zacks Investment Research raised ZIOPHARM Oncology from a hold rating to a buy rating and set a $3.75 price target for the company in a report on Friday, December 7th. Raymond James raised ZIOPHARM Oncology from a market perform rating to an outperform rating and set a $5.00 price target for the company in a report on Thursday, November 15th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus price target of $4.92.

NASDAQ:ZIOP traded down $0.01 during mid-day trading on Thursday, hitting $3.51. 33,431 shares of the company traded hands, compared to its average volume of 1,575,504. ZIOPHARM Oncology has a one year low of $1.56 and a one year high of $5.00. The firm has a market capitalization of $563.96 million, a PE ratio of -7.40 and a beta of 2.59.

A number of large investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its stake in shares of ZIOPHARM Oncology by 10.3% in the fourth quarter. Geode Capital Management LLC now owns 1,552,016 shares of the biotechnology company’s stock worth $2,902,000 after acquiring an additional 145,129 shares during the period. MSD Partners L.P. boosted its stake in shares of ZIOPHARM Oncology by 222.1% in the fourth quarter. MSD Partners L.P. now owns 10,986,258 shares of the biotechnology company’s stock worth $20,544,000 after acquiring an additional 7,575,758 shares during the period. Amalgamated Bank bought a new position in shares of ZIOPHARM Oncology in the fourth quarter worth about $37,000. Legal & General Group Plc boosted its stake in shares of ZIOPHARM Oncology by 30.6% in the fourth quarter. Legal & General Group Plc now owns 25,865 shares of the biotechnology company’s stock worth $48,000 after acquiring an additional 6,054 shares during the period. Finally, Jane Street Group LLC boosted its stake in shares of ZIOPHARM Oncology by 121.5% in the fourth quarter. Jane Street Group LLC now owns 111,224 shares of the biotechnology company’s stock worth $208,000 after acquiring an additional 61,012 shares during the period. 38.07% of the stock is owned by institutional investors and hedge funds.

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion.

Featured Story: Trading Strategy Methods and Types

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Bean Cash Price Hits $0.0014 on Major Exchanges
Bean Cash Price Hits $0.0014 on Major Exchanges
$1.93 Earnings Per Share Expected for United Parcel Service, Inc.  This Quarter
$1.93 Earnings Per Share Expected for United Parcel Service, Inc. This Quarter
RDI Reit  Reaches New 12-Month Low at $116.80
RDI Reit Reaches New 12-Month Low at $116.80
Contourglobal PLC  Insider Purchases £20,573.40 in Stock
Contourglobal PLC Insider Purchases £20,573.40 in Stock
Crowdholding Tops 24 Hour Trading Volume of $240.00
Crowdholding Tops 24 Hour Trading Volume of $240.00
Head-To-Head Survey: Freestone Resources  and Weatherford International
Head-To-Head Survey: Freestone Resources and Weatherford International


© 2006-2019 Ticker Report